Business Context and Reporting Period
This Form 8-K is a current report filed by InMed Pharmaceuticals Inc. on March 2, 2021. The filing addresses Item 5.02(f), specifically correcting a disclosure error regarding bonus compensation omitted from the Summary Compensation Table in the Company's previously filed Form S-1 Registration Statement (effective November 12, 2020). The compensation data pertains to the fiscal year ended June 30, 2020.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
| Executive Officer | Position | 2020 Total Compensation (USD) | 2020 Bonus Component (USD) |
|---|---|---|---|
| Eric A. Adams | President and CEO | $737,413 | $136,500 |
| Bruce Colwill | Chief Financial Officer | $370,228 | $85,830 |
| Alexandra Mancini | Sr. Vice President, Clinical & Regulatory Affairs | $417,842 | $78,058 |
Note: Compensation is reported in U.S. dollars, converted from Canadian dollars using an exchange rate of U.S.$1.00 = C$1.3426.
Material Changes Versus Prior Period
The filing corrects a misclassification in the prior Registration Statement where undetermined compensation was labeled as "non-equity incentive plan compensation" rather than "bonus awards." The total compensation for the fiscal year 2020 was updated to reflect two bonus payments made to the Named Executive Officers (NEOs):
- November 30, 2020: Initial bonus awards representing 50% of potential bonuses.
- February 26, 2021: Additional bonus awards equal to the November amounts, triggered by the completion of a private placement on February 12, 2021.
Comparing 2020 to 2019, total compensation increased for all three executives due to the inclusion of these bonus awards and salary adjustments.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, or discussion of general business risks. The primary contingency noted is the dependency of the second bonus tranche on the successful completion of the Company's private placement, which occurred on February 12, 2021.
Investor Verification Checklist
- Verify the corrected Summary Compensation Table in the amended Form S-1 Registration Statement.
- Confirm the details of the private placement completed on February 12, 2021, which triggered the second bonus payment.
- Review the Company's Compensation Committee policies regarding performance-based bonuses and private placement milestones.
- Check for any subsequent filings regarding the valuation of option-based awards for the fiscal year 2020.